Works matching DE "AFLIBERCEPT"
Results: 337
Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for neovascular age-related macular degeneration.
- Published in:
- Documenta Ophthalmologica, 2022, v. 144, n. 2, p. 99, doi. 10.1007/s10633-021-09863-7
- By:
- Publication type:
- Article
A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2025, v. 263, n. 2, p. 327, doi. 10.1007/s00417-024-06588-6
- By:
- Publication type:
- Article
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3<sup>+</sup>CD11b<sup>+</sup> cells.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 12, p. 3881, doi. 10.1007/s00417-024-06560-4
- By:
- Publication type:
- Article
Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naïve age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 11, p. 3483, doi. 10.1007/s00417-024-06519-5
- By:
- Publication type:
- Article
The impact of Vitreo-Macular interface abnormalities on the response to Anti-VEGF therapy for centre involving diabetic macular oedema.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 11, p. 3501, doi. 10.1007/s00417-024-06518-6
- By:
- Publication type:
- Article
Influence of submacular hemorrhage at baseline on the long-term outcomes of aflibercept treatment for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 10, p. 3099, doi. 10.1007/s00417-024-06453-6
- By:
- Publication type:
- Article
Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 8, p. 2439, doi. 10.1007/s00417-024-06377-1
- By:
- Publication type:
- Article
Comparative efficacy of brolucizumab, half-dose photodynamic therapy, and aflibercept in managing chronic central serous chorioretinopathy.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 6, p. 1755, doi. 10.1007/s00417-024-06373-5
- By:
- Publication type:
- Article
Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2024, v. 262, n. 1, p. 43, doi. 10.1007/s00417-023-06222-x
- By:
- Publication type:
- Article
Predictive factors for outcomes of half-dose photodynamic therapy combined with aflibercept for pachychoroid neovasculopathy.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2023, v. 261, n. 8, p. 2235, doi. 10.1007/s00417-023-06030-3
- By:
- Publication type:
- Article
Simultaneous intravitreal aflibercept and gas injections for submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2023, v. 261, n. 6, p. 1545, doi. 10.1007/s00417-022-05922-0
- By:
- Publication type:
- Article
Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2023, v. 261, n. 4, p. 959, doi. 10.1007/s00417-022-05900-6
- By:
- Publication type:
- Article
Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2023, v. 261, n. 2, p. 345, doi. 10.1007/s00417-022-05793-5
- By:
- Publication type:
- Article
Correction to: Intravitreal aflibercept for diabetic macular edema in real‑world clinical practice in Japan: 24‑month outcomes.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Comparison of 3-year outcomes of photodynamic therapy combined with intravitreal ranibizumab or aflibercept for polypoidal choroidal vasculopathy in a European cohort.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 11, p. 3533, doi. 10.1007/s00417-022-05724-4
- By:
- Publication type:
- Article
Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 11, p. 3489, doi. 10.1007/s00417-022-05703-9
- By:
- Publication type:
- Article
PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 10, p. 3185, doi. 10.1007/s00417-022-05679-6
- By:
- Publication type:
- Article
Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 8, p. 2561, doi. 10.1007/s00417-022-05634-5
- By:
- Publication type:
- Article
Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 8, p. 2509, doi. 10.1007/s00417-022-05601-0
- By:
- Publication type:
- Article
Correction to: Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 7, p. 2239, doi. 10.1007/s00417-021-05547-9
- By:
- Publication type:
- Article
Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 4, p. 1083, doi. 10.1007/s00417-021-05359-x
- By:
- Publication type:
- Article
Changes of retinal oxygen saturation during treatment of diabetic macular edema with a pre-defined regimen of aflibercept: a prospective study.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2022, v. 260, n. 2, p. 451, doi. 10.1007/s00417-021-05319-5
- By:
- Publication type:
- Article
Intravitreal air bubbles following intravitreal injections: a comprehensive analysis.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2021, v. 259, n. 12, p. 3697, doi. 10.1007/s00417-021-05302-0
- By:
- Publication type:
- Article
Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2021, v. 259, n. 12, p. 3637, doi. 10.1007/s00417-021-05293-y
- By:
- Publication type:
- Article
Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2021, v. 259, n. 10, p. 2879, doi. 10.1007/s00417-021-05150-y
- By:
- Publication type:
- Article
PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2021, v. 259, n. 8, p. 2213, doi. 10.1007/s00417-021-05073-8
- By:
- Publication type:
- Article
Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2021, v. 259, n. 8, p. 2085, doi. 10.1007/s00417-020-05059-y
- By:
- Publication type:
- Article
Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis.
- Published in:
- Graefe's Archive of Clinical & Experimental Ophthalmology, 2021, v. 259, n. 8, p. 2181, doi. 10.1007/s00417-020-05048-1
- By:
- Publication type:
- Article
High-dose Aflibercept with Increased Dosing Intervals as a New Standard of Care for DMO and nAMD.
- Published in:
- touchREVIEWS in Ophthalmology, 2023, v. 17, n. 1, p. 8, doi. 10.17925/usor.2023.17.1.8
- By:
- Publication type:
- Article
Comparison of the effects of 3 different anti-VEGF drugs on cornea thickness, lens thickness and anterior chamber depth: Case-Control Study.
- Published in:
- Medicine Science, 2023, v. 12, n. 1, p. 76, doi. 10.5455/medscience.2023.01.02
- By:
- Publication type:
- Article
雷珠单抗与阿柏西普玻璃体腔注射治疗渗出性年龄相关性黄斑变性的疗效观察.
- Published in:
- Progress in Modern Biomedicine, 2019, v. 19, n. 21, p. 4129, doi. 10.13241/j.cnki.pmb.2019.21.029
- By:
- Publication type:
- Article
Anti-Vascular Endothelial Growth Factor Therapy Regimens for Polypoidal Choroidal Vasculopathy: A Systematic Review.
- Published in:
- Ophthalmologica, 2023, v. 246, n. 3/4, p. 245, doi. 10.1159/000533529
- By:
- Publication type:
- Article
Optical Coherence Tomography Angiography in Diabetic Macular Edema Treated with Intravitreal Aflibercept: A 48-Week Observational Study (the DOCTA Study).
- Published in:
- Ophthalmologica, 2023, v. 246, n. 2, p. 71, doi. 10.1159/000528426
- By:
- Publication type:
- Article
Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
- Published in:
- Ophthalmologica, 2022, v. 245, n. 5, p. 413, doi. 10.1159/000526044
- By:
- Publication type:
- Article
Combination Therapy with N-Acetylserotonin and Aflibercept Activated the Akt/Nrf2 Pathway to Inhibit Apoptosis and Oxidative Stress in Rats with Retinal Ischemia–Reperfusion Injury.
- Published in:
- Current Eye Research, 2024, v. 49, n. 3, p. 280, doi. 10.1080/02713683.2023.2276059
- By:
- Publication type:
- Article
Simultaneous Release of Aflibercept and Dexamethasone from an Ocular Drug Delivery System.
- Published in:
- Current Eye Research, 2022, v. 47, n. 7, p. 1034, doi. 10.1080/02713683.2022.2053166
- By:
- Publication type:
- Article
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX‐bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 11, p. 1978, doi. 10.1002/ijc.34166
- By:
- Publication type:
- Article
Successful delivery of subretinal aflibercept (new surgical technique) for the treatment of submacular hemorrhage in idiopathic polypoidal choroidal vasculopathy.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Real-world visual acuity outcomes for patients with naïve neovascular age-related macular degeneration treated with aflibercept, ranibizumab, or bevacizumab in the Republic of Korea.
- Published in:
- PLoS ONE, 2024, v. 19, n. 10, p. 1, doi. 10.1371/journal.pone.0310381
- By:
- Publication type:
- Article
Effects of aflibercept and bevacizumab on cell viability, cell metabolism and inflammation in hypoxic human Müller cells.
- Published in:
- PLoS ONE, 2024, v. 19, n. 3, p. 1, doi. 10.1371/journal.pone.0300370
- By:
- Publication type:
- Article
Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 2, p. 556, doi. 10.3390/ijms26020556
- By:
- Publication type:
- Article
Aflibercept Off-Target Effects in Diabetic Macular Edema: An In Silico Modeling Approach.
- Published in:
- International Journal of Molecular Sciences, 2024, v. 25, n. 7, p. 3621, doi. 10.3390/ijms25073621
- By:
- Publication type:
- Article
Site-Specific Glycan Microheterogeneity Evaluation of Aflibercept Fusion Protein by Glycopeptide-Based LC-MSMS Mapping.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 19, p. 11807, doi. 10.3390/ijms231911807
- By:
- Publication type:
- Article
Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 16, p. 9424, doi. 10.3390/ijms23169424
- By:
- Publication type:
- Article
Herniation of orbital fat -- analysis of the surgical repair.
- Published in:
- Ophthalmology Journal (2450-7873), 2021, p. 161, doi. 10.5603/OJ.2021.0029
- By:
- Publication type:
- Article
Comparison of the efficiency of subconjunctival aflibercept ranibizumab and bevacizumab in corneal neovascularization in a rat model.
- Published in:
- Ophthalmology Journal (2450-7873), 2021, p. 155, doi. 10.5603/OJ.2021.0026
- By:
- Publication type:
- Article
Patolojik Miyopiye Sekonder Koroidal Neovaskülarizasyon Olgularında Farklı Anti-VEGF Ajanların Etkinliğinin Karşılaştırılması: 4 Yıllık Gerçek Yaşam Verileri.
- Published in:
- MN Opthalmology / MN Oftalmoloji, 2024, v. 31, n. 4, p. 190
- By:
- Publication type:
- Article
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma.
- Published in:
- Siriraj Medical Journal, 2022, v. 74, n. 1, p. 27, doi. 10.33192/Smj.2022.4
- By:
- Publication type:
- Article